Agenus. has been granted a patent for antibodies that specifically target and inhibit the function of TIM-3, a protein involved in immune regulation. The patent includes details on the antibodies, their encoding nucleic acids, and methods for therapeutic use. GlobalData’s report on Agenus gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agenus, Personalized cancer vaccines was a key innovation area identified from patents. Agenus's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting and antagonizing tim-3 function
The granted patent US12011481B2 describes an isolated antibody that specifically targets human T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). The antibody is characterized by its heavy chain variable region (VH) and light chain variable region (VL), each comprising specific complementarity determining regions (CDRs). The claims detail various combinations of amino acid sequences for these regions, with the VH including sequences from SEQ ID NOs: 24, 25, and 26, and the VL from SEQ ID NOs: 37, 39, 40, 41, 44, and 47. The patent also specifies that the VH and VL can exhibit at least 95% identity to these sequences, allowing for variations while maintaining specificity.
Additionally, the patent outlines the potential for the antibody to include specific heavy and light chain constant regions, including variants of human IgG and IgA. Notably, the heavy chain constant region may feature mutations that alter its binding affinity to human Fc gamma receptors, which could influence therapeutic efficacy. The claims further encompass pharmaceutical compositions containing the isolated antibody along with acceptable carriers or excipients, as well as polypeptides corresponding to the heavy and light chains of the antibody. This patent provides a comprehensive framework for the development of TIM-3 targeting antibodies, which may have significant implications in therapeutic applications, particularly in immunology and oncology.
To know more about GlobalData’s detailed insights on Agenus, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
